| Title |
Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx - TPF-C-HIT
|
|---|---|
| Published in |
BMC Cancer, May 2011
|
| DOI | 10.1186/1471-2407-11-182 |
| Pubmed ID | |
| Authors |
Alexandra D Jensen, Jürgen Krauss, Karin Potthoff, Almaz Desta, Gregor Habl, Athanasios Mavtratzas, Christine Windemuth-Kiesselbach, Jürgen Debus, Marc W Münter |
| Abstract |
Long-term locoregional control in locally advanced squamous cell carcinoma of the head and neck (SCCHN) remains challenging. While recent years have seen various approaches to improve outcome by intensification of treatment schedules through introduction of novel induction and combination chemotherapy regimen and altered fractionation regimen, patient tolerance to higher treatment intensities is limited by accompanying side-effects. Combined radioimmunotherapy with cetuximab as well as modern radiotherapy techniques such as intensity-modulated radiotherapy (IMRT) and carbon ion therapy (C12) are able to limit toxicity while maintaining treatment effects. In order to achieve maximum efficacy with yet acceptable toxicity, this sequential phase II trial combines induction chemotherapy with docetaxel, cisplatin, and 5-FU (TPF) followed by radioimmunotherapy with cetuximab as IMRT plus carbon ion boost. We expect this approach to result in increased cure rates with yet manageable accompanying toxicity. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | 4% |
| Japan | 1 | 2% |
| France | 1 | 2% |
| Belgium | 1 | 2% |
| Unknown | 48 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 19% |
| Other | 9 | 17% |
| Student > Doctoral Student | 6 | 11% |
| Student > Bachelor | 6 | 11% |
| Student > Master | 6 | 11% |
| Other | 10 | 19% |
| Unknown | 6 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 57% |
| Agricultural and Biological Sciences | 3 | 6% |
| Nursing and Health Professions | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Mathematics | 1 | 2% |
| Other | 3 | 6% |
| Unknown | 12 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 October 2011.
All research outputs
#18,297,449
of 22,653,392 outputs
Outputs from BMC Cancer
#5,415
of 8,237 outputs
Outputs of similar age
#95,962
of 111,787 outputs
Outputs of similar age from BMC Cancer
#53
of 71 outputs
Altmetric has tracked 22,653,392 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,237 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 111,787 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.